The European Commission today announced that it has reserved an additional 1.8 billion doses of the coronavirus vaccine developed by Pfizer-BioNTech, on behalf of all 27 EU countries, from the end of 2021 to 2023.
Many turn to Boston and North Carolina’s Research Triangle to set up life science companies, but Chicago is now also fast becoming a draw in this respect. The city is emerging as a life science and biopharma hub and seems poised for even further growth, in CGT in particular.
The company reportedly will utilize the investment funding to expand its research platform, and to advance six of its preclinical therapeutic programs.
ERT, Bioclinica merger unites clinical trial tech teams The combination of companies brings together ERT’s clinical endpoint data capabilities and Bioclinica’s imaging, eClinical and drug-safety solutions.
ERT and Bioclinica have sealed the deal on their merger, combining Bioclinica’s imaging, eClinical, and drug-safety capabilities; with ERT’s eCOA, cardiac, respiratory, and wearable expertise. According to company leaders, the union gives clients access to a comprehensive, robust endpoint data collection portfolio.
Joe Eazor now serves as CEO of the merged company, over a management team comprising both ERT and Bioclinica executives. He spoke with Outsourcing-Pharma about the merger and the newly integrated organization’s plans for the coming months.